Novo Nordisk Adr (NVO)

Oct 23, 2025

Eccogene Eyes Hong Kong IPO With Experimental Weight-Loss Drug, AstraZeneca Partnership - Benzinga

Oct 23, 2025

Oct 22, 2025

Novo Nordisk to Convene Extraordinary General Meeting for Board Election - The Globe and Mail

Oct 22, 2025

Oct 22, 2025

Novo Nordisk Announces Extraordinary General Meeting for Board Elections - The Globe and Mail

Oct 22, 2025

Oct 18, 2025

J.P. Morgan Reaffirms Their Buy Rating on Novo Nordisk (0QIU) - The Globe and Mail

Oct 18, 2025

Oct 16, 2025

What's Driving the Market Sentiment Around Novo Nordisk AS? - Sahm

Oct 16, 2025

Oct 16, 2025

Eli Lilly, Novo Nordisk, Hims & Hers Health Shares Move Lower After Trump Calls Out 'Fat-Loss Drugs' - Sahm

Oct 16, 2025

Oct 15, 2025

Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal - Sahm

Oct 15, 2025

Oct 13, 2025

ETFs Investing in Novo Nordisk A/S Sponsored ADR Class B Stocks - TradingView

Oct 13, 2025

Oct 11, 2025

Does Novo Nordisk’s Latest Drug Trial Setback Signal a Chance for Investors in 2025? - Sahm

Oct 11, 2025

Oct 11, 2025

Deutsche Bank Remains a Buy on Novo Nordisk (0QIU) - The Globe and Mail

Oct 11, 2025

Oct 09, 2025

Novo Nordisk To Acquire Liver Disease Focused Akero Therapeutics For Around $5 Billion - Sahm

Oct 09, 2025

Oct 04, 2025

UBS Sticks to Their Hold Rating for Novo Nordisk (0QIU) - The Globe and Mail

Oct 04, 2025

Oct 02, 2025

BMO Capital Remains a Hold on Novo Nordisk (NVO) - The Globe and Mail

Oct 02, 2025

Oct 01, 2025

J.P. Morgan Sticks to Their Buy Rating for Novo Nordisk (0QIU) - The Globe and Mail

Oct 01, 2025

Sep 30, 2025

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk - sharewise.com

Sep 30, 2025

Sep 30, 2025

Deutsche Bank Reaffirms Their Buy Rating on Novo Nordisk (0QIU) - The Globe and Mail

Sep 30, 2025

Sep 28, 2025

Novo Nordisk ADR earnings missed, revenue topped estimates By Investing.com - Investing.com South Africa

Sep 28, 2025

Sep 27, 2025

Novo Nordisk ADR earnings missed, revenue topped estimates - Investing.com India

Sep 27, 2025

Sep 24, 2025

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming DeadlinesNVO | FinancialContent - FinancialContent

Sep 24, 2025

Sep 24, 2025

NVO Stock Quote Price and Forecast - CNN

Sep 24, 2025

Sep 23, 2025

NVO DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important September 30 Deadline in Securities Class Action - GlobeNewswire Inc.

Sep 23, 2025

Sep 20, 2025

NVO IMPORTANT DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors with Losses in Excess of $100K to Secure Counsel Before Important September 30 Deadline in Securities Class Action - GlobeNewswire Inc.

Sep 20, 2025

Sep 19, 2025

Tools to assess Novo Nordisk A s (b Shares) Adrhedged’s risk profileJuly 2025 Setups & Technical Pattern Based Buy Signals - newser.com

Sep 19, 2025

Sep 19, 2025

J.P. Morgan Keeps Their Buy Rating on Novo Nordisk (0QIU) - The Globe and Mail

Sep 19, 2025

Sep 18, 2025

Novo Nordisk And Prudential Stand Out In European ADR Gains - Finimize

Sep 18, 2025

Sep 18, 2025

Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs - Sahm

Sep 18, 2025

Sep 18, 2025

Custom strategy builders for tracking Novo Nordisk A s (b Shares) AdrhedgedStock Surge & AI Forecasted Entry/Exit Points - newser.com

Sep 18, 2025